US FDA extends quality-by-design pilot for biologics
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has extended the deadline for submitting requests to participate in its quality-by-design pilot programme for complex biotech products1. Companies now have an additional year – until 30 September 2010 – to send in their requests2.